HMG-CoA | 26926-09-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: HMG-CoA
• 英文别名: (3S)-5-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethylsulfanyl]-3-hydroxy-3-methyl-5-oxopentanoic acid
• CAS: 26926-09-0；1553-55-5
• 化学式: C₂₇H₄₄N₇O₂₀P₃S
• 分子量: 911.7
• InChiKey: CABVTRNMFUVUDM-VRHQGPGLSA-N

物化性质

• 密度：
  1.87±0.1 g/cm3(Predicted)
• 物理描述：
  Solid
• 碰撞截面：
  259.35 Ų [M-H]- [CCS Type: DT, Method: single field calibrated with Agilent tune mix (Agilent)]

计算性质

• 辛醇/水分配系数(LogP)：
  -6.6
• 重原子数：
  58
• 可旋转键数：
  24
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  447
• 氢给体数：
  11
• 氢受体数：
  25

反应信息

• 作为反应物：
  描述：

  HMG-CoA 、 异丙基-beta-D-硫代半乳糖吡喃糖苷 反应 4.0h， 生成 辅酶 A
  参考文献：
  名称：

  CLASS II HMG-COA REDUCTASE INHIBITORS AND METHODS OF USE

  摘要：

  本发明涉及用于治疗细菌感染的组合物和方法。

  公开号：

  US20130331450A1

文献信息

• [EN] BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS<br/>[FR] COMPOSÉS BENZAMIDE OU BENZAMINE À UTILISER EN TANT QU'ANTICANCÉREUX POUR LE TRAITEMENT DE CANCERS HUMAINS
  申请人：UNIV TEXAS

  公开号：WO2017007634A1

  公开（公告）日：2017-01-12

  The described invention provides small molecule anti-cancer compounds for treating tumors that respond to cholesterol biosynthesis inhibition. The compounds selectively inhibit the cholesterol biosynthetic pathway in tumor-derived cancer cells, but do not affect normally dividing cells.

  所描述的发明提供了用于治疗对胆固醇生物合成抑制作出反应的肿瘤的小分子抗癌化合物。这些化合物选择性地抑制肿瘤来源的癌细胞中的胆固醇生物合成途径，但不影响正常分裂的细胞。
• [EN] CATHEPSIN CYSTEINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉASES À CYSTÉINE DE TYPE CATHEPSINES
  申请人：MERCK SHARP & DOHME

  公开号：WO2015054038A1

  公开（公告）日：2015-04-16

  This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

  这项发明涉及一类新型化合物，它们是半胱氨酸蛋白酶抑制剂，包括但不限于对卡特普辛K、L、S和B的抑制剂。这些化合物可用于治疗需要抑制骨吸收的疾病，如骨质疏松症。
• [EN] THIENOPYRIDONE DERIVATIVES AS AMP-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATORS<br/>[FR] DÉRIVÉS DE THÉNOPYRIDONE COMME ACTIVATEURS DE LA PROTÉINE KINASE DÉPENDANTE DE L'AMP (AMPK)
  申请人：MERCK PATENT GMBH

  公开号：WO2009124636A1

  公开（公告）日：2009-10-15

  The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in claim 1, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diseases and disorders modulated by AMP agonists. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I).

  本发明涉及式(I)的化合物，其中R1、R2和R3如权利要求1所定义，包括其药物组合物以及用于治疗和/或预防由AMP激动剂调节的疾病和紊乱的用途。该发明还涉及中间体和式(I)化合物的制备方法。
• [EN] SQUALENE COMPOUNDS AS MODULATORS OF LDL-RECEPTOR EXPRESSION<br/>[FR] COMPOSÉS DE SQUALÈNE EN TANT QUE MODULATEURS DE L'EXPRESSION DU RÉCEPTEUR LDL
  申请人：ISIS INNOVATION

  公开号：WO2016042318A1

  公开（公告）日：2016-03-24

  The present invention relates to compounds that modify low density lipoprotein receptor (LDLR) expression. The compounds have the structural formula I shown below: wherein m, R1, n, R2 and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with elevated levels of low density lipoprotein cholesterol (LDL-C).

  本发明涉及修改低密度脂蛋白受体（LDLR）表达的化合物。这些化合物具有下面所示的结构式I：其中m、R1、n、R2和R3如本文所定义。本发明还涉及制备这些化合物的方法，包括它们的药物组合物，以及它们在治疗与低密度脂蛋白胆固醇（LDL-C）水平升高相关的疾病或紊乱中的应用。
• Dibenzyl Amine Compounds and Derivatives
  申请人：Chang George

  公开号：US20070213371A1

  公开（公告）日：2007-09-13

  Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

  二苯基胺化合物及其衍生物，含有这种化合物的药物组合物以及使用这种化合物提高某些血浆脂质水平，包括高密度脂蛋白胆固醇，并降低其他一些血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，并据此治疗由高密度脂蛋白胆固醇水平低和/或低密度脂蛋白胆固醇和甘油三酯水平高加重的疾病，如动脉粥样硬化和心血管疾病在某些哺乳动物，包括人类。